Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Novo Nordisk’s Wegovy faces sharp decline in growth forecasts and share value as competition intensifies and compounded drug ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Noom introduces affordable options for obesity treatments, including Novo Nordisk's Wegovy and GLP-1Rx programs. Read more ...

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...